Linked Life Data

12532419

Source:http://linkedlifedata.com/resource/pubmed/id/12532419

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-1-17
pubmed:abstractText
The coding region determinant binding protein (CRD-BP) was isolated by virtue of its high affinity to the c-myc mRNA coding region stability determinant and shown to shield this message from nucleolytic attack, prolonging its half-life. CRD-BP is normally expressed during fetal life but is also activated de novo in tumors. Considering that aberrant CRD-BP expression may represent an additional mechanism interfering with c-myc regulation, we screened 118 primary breast carcinomas for CRD-BP expression, 60 of which had also been analyzed by comparative genomic hybridization (CGH). Copy number gains encompassing 8q24, the chromosome band that contains the c-myc locus, were detected in 48.3% (29/60) of tumors, whereas gains involving band 17q21, which contains the CRD-BP locus, were observed in 18.3% (11/60) of tumors. CRD-BP expression was detected in 58.5% (69/118) of tumors, implying mechanisms of activation alternative to gene amplification. Altogether, some 75% of the tumors had alterations pertaining to c-myc since they either harbored 8q24 gains and/or expressed CRD-BP. Significant associations were detected between CRD-BP expression and the absence of estrogen receptors (p = 0.005) and between the presence of 8q24 gains and an increased number of genomic changes as measured by CGH (p = 0.0017). Tumors were divided into 4 groups according to CRD-BP expression and 8q24 gains. The odds for tumors having both characteristics to be classified as poorly differentiated (grade III vs. grade I and II) were 19.6 times the corresponding odds for tumors neither expressing CRD-BP nor harboring 8q24 gains. For tumors either harboring 8q24 gains only or expressing CRD-BP alone, the corresponding odds were 6.4 and 3, respectively.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
Copyright 2002 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
104
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
54-9
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed-meshheading:12532419-Adult, pubmed-meshheading:12532419-Aged, pubmed-meshheading:12532419-Aged, 80 and over, pubmed-meshheading:12532419-Breast Neoplasms, pubmed-meshheading:12532419-Carcinoma, pubmed-meshheading:12532419-Cell Differentiation, pubmed-meshheading:12532419-Chromosomes, Human, Pair 17, pubmed-meshheading:12532419-Chromosomes, Human, Pair 8, pubmed-meshheading:12532419-Female, pubmed-meshheading:12532419-Gene Amplification, pubmed-meshheading:12532419-Gene Expression Regulation, Neoplastic, pubmed-meshheading:12532419-Genes, myc, pubmed-meshheading:12532419-Humans, pubmed-meshheading:12532419-Middle Aged, pubmed-meshheading:12532419-Neoplasm Proteins, pubmed-meshheading:12532419-Nucleic Acid Hybridization, pubmed-meshheading:12532419-RNA, Messenger, pubmed-meshheading:12532419-RNA, Neoplasm, pubmed-meshheading:12532419-RNA-Binding Proteins, pubmed-meshheading:12532419-Reverse Transcriptase Polymerase Chain Reaction
pubmed:year
2003
pubmed:articleTitle
8q24 Copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomas.
pubmed:affiliation
Department of Genetics, St. Savas Hospital, Athens, Greece. pioannidis@genet.ath.forthnet.gr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't